Neil Brickel, speaking at Late Phase Drug Development World Europe 2011

Neil Brickel,
Safety Development Leader
GSK

Neil qualified from the London Hospital Medical College (University of London) in 1991 and gained Membership of the Royal College of Physicians in 1994.
In October 2000, Neil entered the Pharmaceutical industry, initially in Medical Affairs roles in UCB Pharma UK Ltd. and AstraZeneca UK Ltd for allergy and cardiovascular products, respectively.
In 2005 Neil joined GlaxoSmithKline in the Safety Evaluation and Risk Management group within Global Clinical Safety and Pharmacovigilance, working in both the anti-infectives and Neurosciences therapy areas.
During his time in Pharmaceutical Medicine, Neil has been involved in the UK launches for Xyxal (levocetirizine) and Crestor (rosuvastatin) and has supported the submission activities for Trobalt (retigabine) with various regulatory agencies.

Appearing:

Day One- Wednesday 7th December 2011

9.10am

KEYNOTE: Role of different teams in late phase development – Retigabine, treatment for partial epilepsies, a case study in late stage in-licensing, safety and market access

• Late phase in-licensing and working in collaboration with the heritage company
• Managing parallel NDA/MAA reviews; CHMP questions vs. FDA Ad Com
• Developing the safety strategy to manage the novel pharmacology
• Risk management planning aspects

Neil Brickel,

Safety Development Leader,
GSK

Liz Mitchell,

VP Medicine Development Leader, Neurosciences MDC,
GSK

Samin Saeed,

Senior Medical Advisor,
GSK

Sponsor Late Phase Drug Development World Europe 2011 ›

Premium sponsor